Widely used:
Our Opinion
Recently Viewed
Clear AllValue Research Rating
Our Opinion
Riskometer
Very High
₹17.2782 0.81%
As on 04-Jul-2025
As per SEBI's Riskometer.
Split between different types of investments
Split between categories of Equity investments
|
Fund name
|
Rating |
Our Opinion |
Risk
|
Return (%) |
|
Expense Ratio (%)
|
|---|---|---|---|---|---|---|
|
ICICI Prudential Nifty Pharma Index Fund - Direct Plan
|
|
Very High
|
loading... |
0.37 |
||
|
|
Very High
|
loading... |
0.21 |
|||
 |
|
Very High
|
loading... |
1.05 |
||
 |
|
Very High
|
loading... |
0.89 |
||
|
|
Very High
|
loading... |
0.58 |
₹84 Cr
--
1,000
--
1,000
6
Investment Strategy
The Scheme seeks to invest in companies whose securities are included in Nifty Pharma Index and subject to tracking errors, to endeavor to achieve the returns of the above index. This would be done by investing in all the stocks comprising the Nifty Pharma Index in the same weightage that they represent in Nifty Pharma Index
Suitability
This is a fund that invests mainly in shares of pharmaceutical and healthcare companies.
We believe that investors should avoid funds that have a narrowly defined investment mandate such as this one. Instead, they should invest in flexi-cap funds which provide complete freedom to the fund management team to invest in companies from which it expects maximum gains.
But if you do invest, you must do so only through the SIP route. Click here to read a primer on SIP investing.
Warning: Do not invest in this, or any other pharma sector fund, if you need to redeem your investment in less than seven years.
Capital Gains Taxation
Disclaimer: The tax information has been prepared on a best-effort basis using information available in the public domain and other sources that Value Research considers reliable. This is not meant as tax advice, and we advise you to consult your tax advisor before making any decision. Value Research takes no responsibility and assumes no liability for any loss or damage arising from any investment or redemption decision based on this information.
Dividend Taxation
Subscribers of Value Research Fund Advisor can conveniently invest in the low-cost direct plan of ICICI Prudential Nifty Pharma Index Fund - Direct Plan through the Value Research Fund Advisor website.
Alternatively, mutual funds can also be purchased directly from the respective fund house’s website. For example, ICICI Prudential Nifty Pharma Index Fund - Direct Plan can be bought from the ICICI Prudential Mutual Fund website. In such a case, if you are investing in multiple funds from different fund houses, you will need to transact separately on each fund house’s website.
The third option is to invest offline, by seeking assistance from a mutual fund distributor. Most banks also act as mutual fund distributors, and you can approach your bank for help in completing your investment.
The latest declared NAV of ICICI Prudential Nifty Pharma Index Fund - Direct Plan, is ₹17.2782 as of 08-Jul-2025.
| Company | Percentage of Portfolio |
|---|---|
|
23.72
|
|
|
11.01
|
|
|
10.81
|
|
|
10.01
|
|
|
6.20
|
Over the past five years, ICICI Prudential Nifty Pharma Index Fund - Direct Plan has delivered an annualised return of --% as of 08-Jul-2025.
The minimum investment required to start investing in ICICI Prudential Nifty Pharma Index Fund - Direct Plan is ₹1,000 for the lump sum option and ₹1,000 for the SIP (Systematic Investment Plan) option.
